Denver, CO, November 22, 2022 –(PR.com
)– A Phase III clinical trial of the DCVax®-L cancer vaccine, conducted at the Sarah Cannon Research Institute at HealthONE and other centers internationally, has shown that the vaccine extended median survival and also the “long tail” of extended survival in both newly diagnosed and recurrent glioblastoma brain cancer. The trial results were reported today in a publication co-authored by Michael Pearlman, MD from the Sarah Cannon Research Institute in the prestigious cancer journal JAMA Oncology.
This is the first time in nearly 20 years that a Phase III trial of a systemic treatment has shown such survival extension in newly diagnosed glioblastoma, and the first time in nearly 30 years that a Phase III trial of any type of treatment has shown such survival extension in recurrent glioblastoma.
“We are truly excited to see the meaningful survival extensions glioblastoma patients treated…